{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T03:21:22Z","timestamp":1785468082176,"version":"3.56.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study aimed to determine the incidence and prevalence of multiple myeloma (MM) in Finland in 2015\u20132019, to characterize adult patients newly diagnosed with MM, and to follow-up their overall survival (OS) and treatment patterns until the end of 2020. We sourced the data on inpatient and outpatient diagnoses, outpatient medication use, and date of death from comprehensive, nationwide registers. We identified 2037 incident patients with MM in 2015\u20132019. On average, the annual crude incidence was 8.8 and the age-standardized incidence (World Standard Population) was 3.3 per 100,000. The crude prevalence at the end of 2019 was 32.7 cases per 100,000 inhabitants\u2009\u2265\u200918\u00a0years of age. Median age of the patients at first diagnosis (index date) was 71\u00a0years, and 48% were female, the median follow-up being 2.4\u00a0years. The median OS was estimated at 4.5\u00a0years. The proportion of the patients receiving autologous stem cell transplantation (ASCT) within one year since the index date was 24%, with little variation across study years. Conversely, the proportion of all patients receiving lenalidomide within one year since the index date increased from 27 to 48% overall, and from 39 to 81% among ASCT recipients. The estimated median relapse-free survival after ASCT was 2.9\u00a0years. Information on in-hospital MM medication administrations was available for a subset of the study cohort. In this subset, 85.8% of the patients received immunomodulatory drugs and\/or proteasome inhibitors within the first year after the index date.<\/jats:p>","DOI":"10.1007\/s00277-023-05571-1","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T08:02:12Z","timestamp":1702368132000},"page":"1273-1284","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Recent trends in incidence, survival and treatment of multiple myeloma in Finland \u2013 a nationwide cohort study"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1056-3838","authenticated-orcid":false,"given":"Jarno","family":"Ruotsalainen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0494-3900","authenticated-orcid":false,"given":"Leena","family":"Lehmus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mervi","family":"Putkonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha","family":"Lievonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvar","family":"Kallio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4207-8415","authenticated-orcid":false,"given":"Paavo","family":"Raittinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3843-2741","authenticated-orcid":false,"given":"Milla","family":"Summanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0908-5288","authenticated-orcid":false,"given":"Mikko","family":"Kosunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2953-4757","authenticated-orcid":false,"given":"Maarit Jaana","family":"Korhonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,12]]},"reference":[{"key":"5571_CR1","doi-asserted-by":"publisher","first-page":"e1406","DOI":"10.1634\/THEONCOLOGIST.2020-0141","volume":"25","author":"H Ludwig","year":"2020","unstructured":"Ludwig H, Novis Durie S, Meckl A et al (2020) Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment. Oncologist 25:e1406\u2013e1413. https:\/\/doi.org\/10.1634\/THEONCOLOGIST.2020-0141","journal-title":"Oncologist"},{"key":"5571_CR2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/ejh.13083","volume":"101","author":"I Turesson","year":"2018","unstructured":"Turesson I, Bjorkholm M, Blimark CH et al (2018) Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival. Eur J Haematol 101:237\u2013244. https:\/\/doi.org\/10.1111\/ejh.13083","journal-title":"Eur J Haematol"},{"key":"5571_CR3","doi-asserted-by":"publisher","first-page":"e009584","DOI":"10.1136\/bmjopen-2015-009584","volume":"6","author":"R V\u00e9lez","year":"2016","unstructured":"V\u00e9lez R, Turesson I, Landgren O et al (2016) Incidence of multiple myeloma in Great Britain, Sweden, and Malm\u00f6, Sweden: the impact of differences in case ascertainment on observed incidence trends. BMJ Open 6:e009584. https:\/\/doi.org\/10.1136\/bmjopen-2015-009584","journal-title":"BMJ Open"},{"key":"5571_CR4","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/bjh.16674","volume":"191","author":"\u00d8O Langseth","year":"2020","unstructured":"Langseth \u00d8O, Myklebust T\u00c5, Johannesen TB et al (2020) Incidence and survival of multiple myeloma: a population-based study of 10 524 patients diagnosed 1982\u20132017. Br J Haematol 191:418\u2013425. https:\/\/doi.org\/10.1111\/bjh.16674","journal-title":"Br J Haematol"},{"key":"5571_CR5","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1007\/s00277-021-04481-4","volume":"100","author":"I Toppila","year":"2021","unstructured":"Toppila I, Miettinen T, Lassenius MI et al (2021) Characteristics and survival trends in Finnish multiple myeloma patients-a nationwide real-world evidence study. Ann Hematol 100:1779\u20131787. https:\/\/doi.org\/10.1007\/s00277-021-04481-4","journal-title":"Ann Hematol"},{"key":"5571_CR6","first-page":"1171","volume":"135","author":"M S\u00e4ily","year":"2019","unstructured":"S\u00e4ily M, Silvennoinen R, Jantunen E et al (2019) Monimuotoinen myelooma. Duodecim 135:1171\u20131179","journal-title":"Duodecim"},{"key":"5571_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/ejh.13976","volume":"111","author":"X Leleu","year":"2023","unstructured":"Leleu X, Gorsh B, Bessou A et al (2023) Survival outcomes for patients with multiple myeloma in France: a retrospective cohort study using the Syst\u00e8me National des Donn\u00e9es de Sant\u00e9 national healthcare database. Eur J Haematol 111:125\u2013134. https:\/\/doi.org\/10.1111\/ejh.13976","journal-title":"Eur J Haematol"},{"key":"5571_CR8","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.3324\/haematol.2017.183475","volume":"103","author":"S Thorsteinsdottir","year":"2018","unstructured":"Thorsteinsdottir S, Dickman PW, Landgren O et al (2018) Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study. Haematologica 103:e412\u2013e415. https:\/\/doi.org\/10.3324\/haematol.2017.183475","journal-title":"Haematologica"},{"key":"5571_CR9","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1002\/cam4.1128","volume":"6","author":"H Gregersen","year":"2017","unstructured":"Gregersen H, Vangsted AJ, Abildgaard N et al (2017) The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study. Cancer Med 6:1807\u20131816. https:\/\/doi.org\/10.1002\/cam4.1128","journal-title":"Cancer Med"},{"key":"5571_CR10","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1007\/s00277-022-04959-9","volume":"101","author":"I Toppila","year":"2022","unstructured":"Toppila I, Kysenius K, Miettinen T et al (2022) Comorbidity characteristics of multiple myeloma patients diagnosed in Finland 2005\u20132016. Ann Hematol 101:2485\u20132495. https:\/\/doi.org\/10.1007\/s00277-022-04959-9","journal-title":"Ann Hematol"},{"key":"5571_CR11","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/ejh.13597","volume":"106","author":"IS Sverrisd\u00f3ttir","year":"2021","unstructured":"Sverrisd\u00f3ttir IS, R\u00f6gnvaldsson S, Thorsteinsdottir S et al (2021) Comorbidities in multiple myeloma and implications on survival: a population-based study. Eur J Haematol 106:774\u2013782. https:\/\/doi.org\/10.1111\/ejh.13597","journal-title":"Eur J Haematol"},{"key":"5571_CR12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13045-023-01474-w","volume":"16","author":"N Lopez-Mu\u00f1oz","year":"2023","unstructured":"Lopez-Mu\u00f1oz N, Hern\u00e1ndez-Ibarburu G, Alonso R et al (2023) Large-scale real-life analysis of survival and usage of therapies in multiple myeloma. J Hematol Oncol 16:76. https:\/\/doi.org\/10.1186\/s13045-023-01474-w","journal-title":"J Hematol Oncol"},{"key":"5571_CR13","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/j.1365-2141.2006.06042.x","volume":"133","author":"S Lenhoff","year":"2006","unstructured":"Lenhoff S, Hjorth M, Westin J et al (2006) Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group. Br J Haematol 133:389\u2013396. https:\/\/doi.org\/10.1111\/j.1365-2141.2006.06042.x","journal-title":"Br J Haematol"},{"key":"5571_CR14","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/leu.2014.23","volume":"28","author":"SY Kristinsson","year":"2014","unstructured":"Kristinsson SY, Anderson WF, Landgren O (2014) Improved long-term survival in multiple myeloma up to the age of 80 years. Leukemia 28:1346\u20131348. https:\/\/doi.org\/10.1038\/leu.2014.23","journal-title":"Leukemia"},{"key":"5571_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/EJH.13615","volume":"107","author":"LH Hannig","year":"2021","unstructured":"Hannig LH, Nielsen LK, Ibsen R et al (2021) The impact of changed treatment patterns in multiple myeloma on health-care utilisation and costs, myeloma complications, and survival: a population-based comparison between two time periods in Denmark. Eur J Haematol 107:63\u201373. https:\/\/doi.org\/10.1111\/EJH.13615","journal-title":"Eur J Haematol"},{"key":"5571_CR16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/ejh.13707","volume":"108","author":"CH Blimark","year":"2022","unstructured":"Blimark CH, Vangsted AJ, Klausen TW et al (2022) Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries. Eur J Haematol 108:99\u2013108. https:\/\/doi.org\/10.1111\/ejh.13707","journal-title":"Eur J Haematol"},{"key":"5571_CR17","doi-asserted-by":"publisher","first-page":"S287","DOI":"10.1016\/j.jval.2022.04.010","volume":"25","author":"P Ihalmo","year":"2022","unstructured":"Ihalmo P, V\u00e4\u00e4t\u00e4inen S, Soini E et al (2022) P2 faster access to innovative therapies with risk-sharing agreements - Cancer Medication Reimbursement Decisions from January 2012 to November 2021 in Finland. Value Health 25:S287. https:\/\/doi.org\/10.1016\/j.jval.2022.04.010","journal-title":"Value Health"},{"key":"5571_CR18","unstructured":"Kansallinen hoitosuositus (FMG). In: Suomen Hematologiyhdistys. https:\/\/hematology.fi\/hoito-ohjeet\/hoito-ohje-1\/plasmasolutaudit\/myelooma\/hoito\/kansallinen-hoitosuositus-fmg\/. Accessed 30 May 2023"},{"key":"5571_CR19","unstructured":"Finnish myeloma group (FMG) (2017) Myelooman kansallinen hoitosuositus"},{"key":"5571_CR20","unstructured":"Finnish myeloma group (FMG) (2019) Myelooman kansallinen hoitosuositus"},{"key":"5571_CR21","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E et al (2021) Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up y behalf of the EHA Guidelines Committee * and ESMO Guidelines Committee. Ann Oncol 32:309\u2013322. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.014","journal-title":"Ann Oncol"},{"key":"5571_CR22","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3324\/haematol.2017.178103","volume":"103","author":"CH Blimark","year":"2018","unstructured":"Blimark CH, Turesson I, Genell A et al (2018) Outcome and survival of myeloma patients diagnosed 2008\u20132015. Real-world data on 4904 patients from the Swedish Myeloma Registry. Haematologica 103:506\u2013513. https:\/\/doi.org\/10.3324\/haematol.2017.178103","journal-title":"Haematologica"},{"key":"5571_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/CLEP.S282475","volume":"13","author":"JF Ludvigsson","year":"2021","unstructured":"Ludvigsson JF, Appelros P, Askling J et al (2021) Adaptation of the Charlson Comorbidity Index for register-based research in Sweden. Clin Epidemiol 13:21\u201341. https:\/\/doi.org\/10.2147\/CLEP.S282475","journal-title":"Clin Epidemiol"},{"key":"5571_CR24","doi-asserted-by":"publisher","unstructured":"Loponen H, Meht\u00e4l\u00e4 J, Ylisaukko-oja T et al (2023) Real-world experience of novel multiple myeloma treatments in a large, single-center cohort in Finland. eJHaem 4:1019\u20131029. https:\/\/doi.org\/10.1002\/jha2.802","DOI":"10.1002\/jha2.802"},{"key":"5571_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"RA Kyle","year":"2003","unstructured":"Kyle RA, Gertz MA, Witzig TE et al (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78:21\u201333. https:\/\/doi.org\/10.4065\/78.1.21","journal-title":"Mayo Clin Proc"},{"key":"5571_CR26","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.3324\/haematol.2021.280424","volume":"108","author":"KLF Moore","year":"2022","unstructured":"Moore KLF, Turesson I, Genell A et al (2022) Improved survival in myeloma patients\u2013a nationwide registry study of 4,647 patients \u226575 years treated in Denmark and Sweden. Haematologica 108:1640\u20131651. https:\/\/doi.org\/10.3324\/haematol.2021.280424","journal-title":"Haematologica"},{"key":"5571_CR27","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.clml.2019.10.014","volume":"20","author":"E Kastritis","year":"2020","unstructured":"Kastritis E, Roussou M, Eleutherakis-Papaiakovou E et al (2020) Early relapse after autologous transplant is associated with very poor survival and identifies an ultra-high-risk group of patients with myeloma. Clin Lymphoma Myeloma Leuk 20:445\u2013452. https:\/\/doi.org\/10.1016\/j.clml.2019.10.014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5571_CR28","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/EJH.13464","volume":"105","author":"F Schjesvold","year":"2020","unstructured":"Schjesvold F (2020) Evolution of diagnostic workup and treatment for multiple myeloma 2013\u20132019. Eur J Haematol 105:434\u2013448. https:\/\/doi.org\/10.1111\/EJH.13464","journal-title":"Eur J Haematol"},{"key":"5571_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejca.2017.02.017","volume":"77","author":"MK Leinonen","year":"2017","unstructured":"Leinonen MK, Miettinen J, Heikkinen S et al (2017) Quality measures of the population-based Finnish Cancer Registry indicate sound data quality for solid malignant tumours. Eur J Cancer 77:31\u201339. https:\/\/doi.org\/10.1016\/j.ejca.2017.02.017","journal-title":"Eur J Cancer"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05571-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05571-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05571-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T10:07:00Z","timestamp":1710410820000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05571-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,12]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["5571"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05571-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,12]]},"assertion":[{"value":"6 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.This register-based study was approved by each register holder.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"LL and MK are employed by Pfizer Oy and own Pfizer stocks. MS is a former employee of Pfizer Oy. MP declares honoraria for lectures from and membership on advisory boards with BMS, Janssen, Pfizer and Sanofi, and consultancy for Janssen and Pfizer. JL has received consultancy fees from Bristol-Myers Squibb. JR, MJK, PR and AK are employees of Oriola Finland Oy, which received funding from Pfizer Oy in connection with the development of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interests"}}]}}